A new report from Motilal Oswal notes that increasingly Indian pharma companies are finding it hard to meet the compliance criteria set by USFDA, leading to regulatory hurdles for the US generics market.
By identifying areas to improve the use of natural resources in different stages of production, the pharma industry is contributing toward circular economies of scale.
Officials said that they are closely monitoring the developments and ensuring the well-being of their staff in that region is the first and foremost priority.